eFFECTOR Therapeutics (EFTR) Issues Pipeline and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
eFFECTOR Therapeutics Provides Pipeline and Business Updates
January 24, 2022 4:00 PM ESTTomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 1% patient population, representing additional $5 billion U.S. market opportunity
First patients dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and in combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer
Company enters into investment agreement with Lincoln Park Capital for up to $50... More
